Seek truth from facts, competitive symbiosis
Zhengqing Group made its debut at a major event in the traditional Chinese medicine immunology sector, where an academician shared Zhengqing Fengtongning’s groundbreaking innovations.
Category:
Release time:
2026-07-23
On July 18, Academician Liu Liang delivered a keynote address titled “Original Theories of Traditional Chinese Medicine and Research on the Prevention and Control of Major Chronic Diseases.” Grounded in the TCM principle of “adapting treatment to the three factors,” he systematically expounded upon the guidance provided by this approach. Corytine alkaloid The latest advances in time‑targeted drug delivery for the treatment of arthritis are highlighted, with a particular focus on an innovative formulation—the Zhengqing Fengtongning Time‑Release Micro‑Pellet Capsule. Patients with rheumatoid arthritis commonly experience morning joint stiffness and exacerbated pain, symptoms that traditional administration methods fail to align with the body’s diurnal immune rhythms, thereby limiting therapeutic efficacy. This pulse‑release micro‑pellet capsule leverages… Chronopharmacology The research and development effort enables precise control over the timing of drug release, specifically targeting and alleviating the core symptom of “morning stiffness” in patients with rheumatic diseases, thereby offering a novel solution for precision‑timed therapy in rheumatic and immune disorders. The findings have received unanimous recognition and high praise from the experts in attendance.
Academician Liu Liang’s research team has been deeply engaged in the study of Qingfengteng and sinomenine for more than thirty years. Zhengqing Fengtongning As the only single‑component traditional Chinese medicine anti‑rheumatic formulation in China to be included in both the National Essential Medicines List and the National Medical Insurance Drug List, it leverages the unique anti‑inflammatory and immunomodulatory mechanisms of sinomenine and has been widely used in clinical practice for autoimmune diseases such as rheumatoid arthritis over many years. The recent progress in developing time‑pulse micro‑pellet capsules represents a deep integration of traditional Chinese medicine’s theory of circadian rhythms with modern pharmaceutical technologies, marking a groundbreaking step in upholding the essence of TCM while fostering innovation, and opening new avenues for precision treatment of chronic diseases in TCM.
At the conference, Zhengqing Group set up a dedicated brand booth and maintained an on-site presence throughout the event to facilitate academic exchanges. The booth also hosted a prize‑winning interactive quiz, engaging experts and clinicians from across the country in in‑depth discussions on topics such as the pharmacological mechanisms of qingteng alkaloids, the clinical applications of Zhengqing Fengtongning, and innovative timing‑based drug‑administration techniques. Through these activities, the company comprehensively showcased its research heritage, cutting‑edge products, and comprehensive clinical solutions in the field of rheumatology and immunology, thereby strengthening industry‑wide academic dialogue and expanding channels for clinical product promotion.
This conference also features a training program on AI‑driven pharmaceutical technologies, focusing on how artificial intelligence is empowering research in traditional Chinese medicine. Academician Liu Liang’s presentation places the modern research on Zhengqing Fengtongning within the cutting‑edge framework of multidisciplinary convergence, underscoring the scientific value and international potential of innovative single‑component formulations derived from traditional Chinese medicine. Looking ahead, Zhengqing Group will continue to leverage academician‑led research platforms, deepen its expertise in the field of TCM‑based immunology, and steadily advance the iterative development and upgrading of the Zhengqing Fengtongning product line. By delivering original, innovative TCM breakthroughs, the company aims to support standardized diagnosis and treatment of rheumatic diseases, promote the modernization and internationalization of TCM, and provide high‑quality TCM therapeutic solutions for patients with autoimmune disorders worldwide.
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地